GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Astrazeneca Plc (AZN) [hlAlert]

Rating:
Outperform
AZN
up 1.68 %

Astrazeneca Plc (AZN) rated Outperform with price target $75 by Leerink Swann

Posted on: Thursday,  Feb 27, 2014  9:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Astrazeneca Plc (NYSE: AZN) on 02/27/2014. Previously Leerink Swann rated Outperform Astrazeneca Plc (NYSE: AZN) on
01/14/2014., when the stock price was $31.09. Since then, Astrazeneca Plc has gained 1.69% as of 01/19/2016's recent price of $31.61.
If you would have followed the previous Leerink Swann 's recommendation on AZN, you would have gained 1.68% of your investment in 735 days.

AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. The Company?s product portfolio comprise: Arimidex, Crestor, Nexium, Seroquel and Symbicort. It has operations in various markets, such as China, United Kingdom, Sweden and the United States. It has 26 manufacturing sites in 18 countries. Cardiovascular product pipeline includes Saxagliptin, Dapagliflozin, Atherosclerosis/dyslipidaemia, Thrombosis and Atrial fibrillation. Gastrointestinal pipeline includes life cycle management initiatives. AstraZeneca?s Infection pipeline MedImmune and Dedicated tuberculosis (TB) research. Oncology product pipeline includes Zactima (vandetanib), Zactima (vandetanib), ZD4054 and MedImmune.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/27/2014 9:25 AM Buy
None
34.19 37.50
as of 10/17/2014
1 Week down  -0.87 %
1 Month down  -7.43 %
3 Months down  -7.03 %
1 YTD down  -0.83 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/14/2014 8:25 AM Buy
None
31.09

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy